📋 Tender Overview
The subject of this publication is the conclusion of non-exclusive discount agreements for pharmaceuticals containing the active ingredient Rotigotin (ATC code according to WHO: N04BC09), excluding packages larger than 84 units. The contract will be concluded within the framework of an Open-House model, meaning that the contract conclusion is open to all interested pharmaceutical companies during the participation period, provided they meet the participation requirements and accept them. This implies that individual contract negotiations will not be conducted and exclusivity is not granted. The quantity to be purchased is unknown, as it depends on demand and the development of the insured population, the prescribing behavior of doctors, and the dispensing and stocking behavior of public pharmacies. Minimum purchase quantities are therefore not guaranteed. Rotigotin